Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit
cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at
opm.gov.
Multidrug-resistant Tuberculosis and HIV: Composition of Strains and Biomarkers of Treatment Response
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
International Research Scientist Development Award (IRSDA)
Project Information in NIH RePORTER
Multidrug-resistant Tuberculosis and HIV: Composition of Strains and Biomarkers of Treatment Response
Principal Institution
Yale University
Principal Investigator(s) (PI)
Cudahy, Patrick George Tobias
Project Contact Information
Email:
patrick.cudahy@yale.edu
Year(s) Awarded
2019-2024
Country
South Africa
Collaborators
Doris Goodwin Hospital
University of KwaZulu-Natal
Project Description
This research will identify clinically-relevant host markers of multidrug-resistant tuberculosis (MDR-TB) treatment response among people co-infected with HIV, a patient population that suffers very high levels of on-treatment mortality. These studies will also provide new insights into the within-patient complexity of
Mycobacterium tuberculosis before and during treatment. Improved markers of treatment response and a better understanding of the mechanisms that limit the effectiveness of treatment can contribute to better outcomes for HIV/MDR-TB patients and prevent the emergence and transmission of even more resistant forms of tuberculosis.
Related World Regions / Countries
Related Global Health Research Topics